Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors

Add time:07/19/2019    Source:sciencedirect.com

36 new compounds with the typical skeleton of 4-anilino-5-vinyl/ethynyl pyrimidine, 4-anilino-3-cyano-5-vinyl/ethynyl/phenyl pyridine, and m-amino-N-phenylbenzamide, are designed, synthesized and selectively tested on EGFR, ErbB-2 kinases, and A-549, HL60 cells growth inhibition. Results from the bioactivity and chemical structures yield preliminary structure–activity relationships (SARs). The most potent 5-ethynylpyrimidine derivative 20a has an IC50 value of 45 nM to EGFR kinase. Several compounds of other series also show IC50 values <1 μM for EGFR and <5 μM for A-549 and HL60 cells growth inhibition.

We also recommend Trading Suppliers and Manufacturers of 3-Cyano-5-phenylpyridine (cas 10177-11-4). Pls Click Website Link as below: cas 10177-11-4 suppliers

Prev:Mannich bases of scutellarein as thrombin-inhibitors: Design, synthesis, biological activity and solubility
Next:The small chemical enzyme inhibitor 5-PHENYLNICOTINIC ACID (cas 10177-12-5)/CD13 inhibits cell migration and invasion of tartrate-resistant acid phosphatase/ACP5-overexpressing MDA-MB-231 breast cancer cells)